Discover the best publications about Antibody-drug Conjugates (ADCs) selected and recommended by the editors of ADC Review / Journal of Antibody-drug Conjugates:
This authoritative volume provides a holistic picture of antibody-drug conjugates (ADCs). Fourteen comprehensive chapters are divided into six sections including an introduction to ADCs, the ADC construct, development issues, landscape, IP and pharmacoeconomics, case studies, and the future of the field.
The book examines everything from the selection of the antibody, the drug, and the linker to a discussion of developmental issues such as formulations, bio-analysis, pharmacokinetic-pharmacodynamic relationships, and toxicological and regulatory challenges. It also explores pharmacoecomonics and intellectual properties, including recently issued patents and the cost analysis of drug therapy.
Case studies are presented in this publication for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg®), brentuximab vedotin (Adcetris®), and ado-trastuzumab emtansine (Kadcyla®), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011).
Finally, this volume presents a perspective by the editors on the future directions of ADC development and clinical applications. Antibody-Drug Conjugates is a practical and systematic resource for scientists, professors, and students interested in expanding their knowledge of cutting-edge research in this exciting field.
Publication Date: September 10, 2013 | ISBN-10: 3319130803 | ISBN-13: 978-3319130804 | Edition: 2015
Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for cancer patients by combining the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutic drugs.
In Antibody-Drug Conjugates, expert researchers provide detailed protocols for many of the key ADC techniques necessary for working in the field. These chapters and methodologies are aimed at the key tasks necessary to identify a suitable target, properly design the mAb, the linker and the payload, as well as to conjugate them in a reproducible and scalable fashion.
Written in the highly successful Methods in Molecular Biology™ format, these detailed chapters include the kind of practical implementation advice that guarantees quality results.
Authoritative and timely, Antibody-Drug Conjugates aims to further drive ADC development and thus help toward improving cancer treatments of the future.
Click on the link to order Antibody-Drug Conjugates (Methods in Molecular Biology).
Publication Date: September 10, 2013 | ISBN-10: 1627035400 | ISBN-13: 978-1627035408 | Edition:2013
The concept of delivering ‘magic bullets’ to treat diseases was first proposed by Paul Erlich in the early 1900’s. The realization of this concept for the treatment of cancer occurred in the late 1990’s with the approval of monoclonal antibody therapies. The use of monoclonal antibodies conjugated (linked) to potent cytotoxic agents (antibody-drug conjugates, ADCs) for specifically delivering cytotoxics to cancer cells was an obvious extension of antibody-based therapy.
ADCs have been under intense investigation for several decades; progress, however, has been limited due to toxicity or lack of improved efficacy compared to unconjugated cytotoxics. More recently, linker technology and target selection have advanced such that several ADCs and immunotoxins are undergoing clinical testing or are approved for use. This important volume gives the latest and most comprehensive information on the topic, describing different types of ADCs and immunotoxins for both hematologic and solid malignancies. Finally, the volume highlights the promise that this technology holds for diverse types of human cancer.
Publication Date: December 12, 2012 | ISBN-10: 1461454557 | ISBN-13: 978-1461454557 | Edition:2013
Monoclonal antibodies have become important treatments for cancer, inflammation and a wide range of other diseases, representing an increasing share of the most successful pharmaceutical markets. The technologies to discover these drugs have been developed by select centers of excellence in industry and academia, and are continually being fine tuned in the race to identify the best antibody-based drug candidates and accelerate their paths to patients.
The objective of this volume is to provide a series of guides to those evaluating and preparing to enter particular areas within the field and to offer specialized perspectives to established researchers. The chapters set into context the significance of key developments and important considerations for selecting different approaches, such as antibody humanization, isotype selection, lead candidate selection criteria and protein production.
All contributors to this work are experts in their fields, and many have played pivotal roles in the creation of these technologies.
Click on the link to order Antibody Drug Discovery (Molecular Medicine and Medicinal Chemistry).
Publication Date: December 2, 2011 | ISBN-10: 1848166281 | ISBN-13: 978-1848166288
The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs—with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protein was launched.
Fusion Protein Technologies for Biopharmaceuticals examines the state of the art in developing fusion proteins for biopharmaceuticals, shedding light on the immense potential inherent in fusion protein design and functionality. A wide pantheon of international scientists and researchers deliver a comprehensive and complete overview of therapeutic fusion proteins, combining the success stories of marketed drugs with the dynamic preclinical and clinical research into novel drugs designed for as yet unmet medical needs.
The book covers the major types of fusion proteins—receptor-traps, immunotoxins, Fc-fusions and peptibodies—while also detailing the approaches for developing, delivering, and improving the stability of fusion proteins. The main body of the book contains three large sections that address issues key to this specialty: strategies for extending the plasma half life, the design of toxic proteins, and utilizing fusion proteins for ultra specific targeting.
The book concludes with novel concepts in this field, including examples of highly relevant multifunctional antibodies. Detailing the innovative science, commercial realities, and brilliant potential of fusion protein therapeutics, Fusion Protein Technologies for Biopharmaceuticals is a must for pharmaceutical scientists, biochemists, medicinal chemists, molecular biologists, pharmacologists, and genetic engineers interested in determining the shape of innovation in the world of biopharmaceuticals.
Publication Date: March 2013 | ISBN-10: 0470646276 | ISBN-13: 978-0470646274
Fish on Prozac. Drugs found in drinking water. India’s drug problem. Chances are you’ve seen these headlines. Human pharmaceuticals represent environmental contaminants of emerging concern, and receive unprecedented attention from the scientific, regulatory and public sectors.
This timely contribution, prepared by international experts in the field, synthesizes and critically examines topics ranging from regulations, environmental chemistry and exposure analysis, to comparative pharmacology, environmental toxicology, water treatment technologies and pharmaceutical take back programs.
Compared to historical contaminants, chemical and biological attributes of human pharmaceuticals present unique challenges to environmental management, but lessons learned from the study of pharmaceuticals promise to advance prospective and retrospective approaches to assess the impacts of industrial chemicals.
Students and environmental scientists, managers, regulators, and public health professionals will benefit from this forward-thinking treatment of human pharmaceuticals in the environment.
Click on the link to order: Human Pharmaceuticals in the Environment: Current and Future Perspectives (Emerging Topics in Ecotoxicology)
Publication Date: July 17, 2014 | ISBN-10: 146143419X | ISBN-13: 978-1461434191 | Edition: 2012
The search to find medicines is as old as disease, which is to say as old as the human race. Through serendipity— by chewing, brewing, and snorting—some Neolithic souls discovered opium, alcohol, snakeroot, juniper, frankincense, and other helpful substances. Ötzi the Iceman, the five-thousand-year-old hunter frozen in the Italian Alps, was found to have whipworms in his intestines and Bronze-age medicine, a worm-killing birch fungus, knotted to his leggings. Nowadays, Big Pharma conglomerates spend billions of dollars on state-of the art laboratories staffed by Ph.D’s to discover blockbuster drugs. Yet, despite our best efforts to engineer cures, luck, trial-and-error, risk, and ingenuity are still fundamental to medical discovery.
The Drug Hunters is a colorful, fact-filled narrative history of the search for new medicines from our Neolithic forebears to the professionals of today, and from quinine and aspirin to Viagra, Prozac, and Lipitor. The chapters offer a lively tour of how new drugs are actually found, the discovery strategies, the mistakes, and the rare successes. Dr. Donald R. Kirsch infuses the book with his own expertise and experiences from thirty-five years of drug hunting, whether searching for life-saving molecules in mudflats by Chesapeake Bay or as a chief science officer and research group leader at major pharmaceutical companies.
Click on the link to order: The Drug Hunters: The Improbable Quest to Discover New Medicines
Publication Date: January 3, 2017 | ISBN-10: 1628727187 | ISBN-13: 978-1628727180
Last Editorial Review: January 16, 2017
Copyright © 2017 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world. Add to Flipboard Magazine.
05 October, 2018
When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000, only a handful of patent applications claiming ADCs had been published. As research cont...
27 September, 2018
Antibody-drug conjugation (ADC) technology has been around for several decades but has yet to reach its full potential in terms of clinical success. In this second article, Penelope Drake and David Rabuka, of...